Skip to main content
. 2022 Oct 7;44(4):877–887. doi: 10.1038/s41401-022-00999-z

Fig. 8. Model of anti-tumor mechanism of compound 19.

Fig. 8

Compound 19 binds to the WBM site of WDR5 and hinders the interaction of WDR5 with its ligand, thus regulating the transcription of genes which are related to ribosomes, cell cycle, DNA replication and apoptosis. Through combining with the WIN site inhibitor, OICR-9492, the anti-tumor effect of WDR5 inhibitors is boosted, providing a potential therapeutic avenue for treating neuroblastoma.